Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Hoth Therapeutics Inc (NQ: HOTH )

2.320 +0.080 (+3.57%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 791,100
Open 2.190
Bid (Size) 2.380 (22)
Ask (Size) 2.390 (24)
Prev. Close 2.240
Today's Range 2.180 - 2.320
52wk Range 1.560 - 7.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication
Initial data reports one of the most critical signaling pathways for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003 
From PR Newswire
FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA)... 
From PR Newswire

Performance

YTD
-7.57%
-7.57%
1 Month
+39.76%
+39.76%
3 Month
+29.61%
+29.61%
6 Month
-18.60%
-18.60%
1 Year
-54.15%
-54.15%

More News

Read More
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
From PR Newswire
Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules
From PR Newswire
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections
From PR Newswire
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment
From PR Newswire
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients
From PR Newswire
Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model
From PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
Tags ADMP LIFE BWAY
From Benzinga
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
From PR Newswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Tags VCNX Benzinga PRVB
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.